FDMT

NASD 4D Molecular Therapeutics, Inc.

Nov 5, 2026 · 3:23 PM ET DELAYED Market Open

$11.37 ↓ -0.91 (-7.41%) Trading Down from the previous close of $12.28, $0.74 below the day’s high of $12.11

YTD change: +51.60%
vs 20-day SMA: -7.36%
vs 200-day SMA: +3.96%

Price ranges

Previous day

$11.51 $12.44

open $12.36 close $12.28

-$0.08 (-0.65%)

Today

$11.16 $12.11

open $12.10 now $11.37

-$0.73 (-6.03%)

Past week

$11.16 $13.46

from $12.93 now $11.37

-$1.56 (-12.06%)

Past month

$10.62 $13.85

from $12.59 now $11.37

-$1.22 (-9.69%)

This year

$6.96 $16.93

from $7.50 now $11.37

+$3.87 (+51.60%)

Price & Performance

+2.57 (+26.47%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 79.4% away from all-time highs of $55.11
FDMT is up 52% since the beginning of the year
FDMT is up 8% over the past 12 months
FDMT is down 10% over the past 1 month
16% of all FDMT investors are betting against FDMT

FDMT reads not so good: price sits above one of the two key moving averages, the 12-month move is +16.8%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-1.04

Earnings momentum +1.0% Quarterly EPS growth

Quarterly change +1.0%

Valuation

P/E ratio N/A

Enterprise value $540.8M

Beta 3.02

Balance sheet & scale

IncomeN/A

Revenue$92.0M

Cash$361.3M

Debt$39.2K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $820.7M

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$478.48	+3.73%
MRNA	Moderna, Inc.	$258.38	+13.11%
RVMD	Revolution Medicines, Inc.	$199.70	+2.82%
ROIV	Roivant Sciences Ltd.	$38.23	+6.08%
BNTX	BioNTech SE Sponsored ADR	$90.70	+4.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.